Pfizer (PFE) Gains from Investment Securities (2009 - 2026)

Pfizer has disclosed Gains from Investment Securities across 18 years of filings, most recently posting -$22.0 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 114.47% year-over-year to -$22.0 million; the TTM figure through Mar 2026 stood at $4.5 billion (up 2366.67% YoY), while the FY2025 annual figure was $4.7 billion, up 1556.54% from the prior year.
• Gains from Investment Securities eased to -$22.0 million in Q1 2026, from $5.0 billion in the prior quarter.
• Over the last five years, Gains from Investment Securities for PFE reached as high as $5.0 billion in Q4 2025 and fell as low as -$2.3 billion in Q4 2023.
• The 5-year median for Gains from Investment Securities is $13.0 million (2024), against an average of $282.7 million.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities plunged 400.0% — and 2023, when it surged 1195.0%.
• A 5-year view of Gains from Investment Securities shows it stood at $200.0 million in 2022, then plunged by 1246.5% to -$2.3 billion in 2023, then soared by 100.57% to $13.0 million in 2024, then surged by 38284.62% to $5.0 billion in 2025, then plunged by 100.44% to -$22.0 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$22.0 million, $5.0 billion, and -$14.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.